World Stem Cell Summit
  • About WSCS
    • About Us
    • Past Speakers
    • Annual Regenerative Medicine Essentials Course
    • 2023 Public Day
    • Symposium Intersection of RegMed & Healthspan
    • Effective Patient Advocacy
    • Regenerative Medicine & the Commercial Space Economy
    • Hot Topics in 2023 at World Stem Cell Summit
  • Partners/Sponsors
    • Partners/Sponsors
    • Sponsorship Opportunities
  • Upcoming Events
  • News & Media
    • News and Opinions
    • WSCS 2023 Photos
    • WSCS Video
  • Contact Us
Select Page

Engineered stem cells target autoimmune diseases

by admin | Jul 19, 2024 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions

Engineered stem cells target autoimmune diseases

By Adam Boros, PhD – Drug Discovery News –

Genetically modified stem cells show promise in a targeted approach to taming inflammation in autoimmune diseases. Researchers developed an immunotherapy using chimeric antigen receptors and mesenchymal stromal cells, paving the way for more precise immunomodulation.

Read the full article by clicking here

More Posts from News Feed

  • Researchers reveal promising treatment target for resistant brain cancer
    Researchers reveal promising treatment target for…
  • Re-engineered, blue light-activated immune cells penetrate and kill solid tumors
    Re-engineered, blue light-activated immune cells…
  • Making Genetically Engineered Stem Cells Viable
    Making Genetically Engineered Stem Cells Viable

Recent Posts

  • CAR NK cell therapy clinical trial puts follicular lymphoma survivor into remission
  • Stem cell therapy linked to lower risk of heart failure after a heart attack
  • Embryo-Like ‘Blood Factories’ Could One Day Supplement Donations
  • Long-Term Growth Hormone Therapy Boosts Pediatric Stem Cells
  • New UCLA drug could restore heart and organ function
  • Parkinson’s treatment tested at UW showing promise in first clinical trial
World Stem Cell Summit Logo - White version
Copyright © 2025 Regenerative Medicine Foundation, All rights reserved.
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow